Pharmaceutical

Ocaliva approval in Europe withdrawn following data re-assessment

Advanz Pharma, Ocaliva’s manufacturer, said thousands of patients will no longer benefit from the treatment.

Sep 4, 2024 - 04:00
Ocaliva approval in Europe withdrawn following data re-assessment
Advanz Pharma, Ocaliva’s manufacturer, said thousands of patients will no longer benefit from the treatment.
Read the original article

Tags:

Previous Article

RegenxBio touts positive data for rare disease drug RGX-121

Next Article

Skyline wins orphan drug designation for retinitis pigmentosa gene therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Dren Bio and Novartis link on bispecific antibodies for cancer

Dren Bio and Novartis link on bispecific antibodies for...

Jul 26, 2024

Jacobio Pharma receives breakthrough therapy designation for glecirasib

Jacobio Pharma receives breakthrough therapy designatio...

Aug 8, 2023

STAT+: Hospitals offer their custom-built tech for sale in search of new revenue streams

STAT+: Hospitals offer their custom-built tech for sale...

Jan 20, 2024